- Home
- ABBV vs PM Comparison
ABBV vs PM Comparison
Compare ABBV & PM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABBV
- PM
- Stock Information
- Founded
- ABBV 2012
- PM 1987
- Country
- ABBV United States
- PM United States
- Employees
- ABBV N/A
- PM N/A
- Industry
- ABBV Biotechnology: Pharmaceutical Preparations
- PM Medicinal Chemicals and Botanical Products
- Sector
- ABBV Health Care
- PM Health Care
- Exchange
- ABBV Nasdaq
- PM Nasdaq
- Market Cap
- ABBV 325.1B
- PM 277.4B
- IPO Year
- ABBV N/A
- PM N/A
- Fundamental
- Price
- ABBV $189.86
- PM $181.72
- Analyst Decision
- ABBV Buy
- PM Strong Buy
- Analyst Count
- ABBV 23
- PM 12
- Target Price
- ABBV $211.55
- PM $164.67
- AVG Volume (30 Days)
- ABBV 6.6M
- PM 5.2M
- Earning Date
- ABBV 07-24-2025
- PM 07-22-2025
- Dividend Yield
- ABBV 3.46%
- PM 2.97%
- EPS Growth
- ABBV N/A
- PM N/A
- EPS
- ABBV 2.34
- PM 4.86
- Revenue
- ABBV $57,367,000,000.00
- PM $38,386,000,000.00
- Revenue This Year
- ABBV $8.50
- PM $11.84
- Revenue Next Year
- ABBV $8.20
- PM $8.26
- P/E Ratio
- ABBV $81.13
- PM $37.39
- Revenue Growth
- ABBV 5.45
- PM 6.78
- 52 Week Low
- ABBV $163.52
- PM $98.93
- 52 Week High
- ABBV $218.66
- PM $183.94
- Technical
- Relative Strength Index (RSI)
- ABBV 55.99
- PM 67.44
- Support Level
- ABBV $185.05
- PM $178.28
- Resistance Level
- ABBV $190.18
- PM $183.94
- Average True Range (ATR)
- ABBV 3.18
- PM 2.84
- MACD
- ABBV 0.75
- PM 0.17
- Stochastic Oscillator
- ABBV 93.85
- PM 83.43
About ABBV AbbVie Inc.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
About PM Philip Morris International Inc
Created from the international operations of Altria in 2008, Philip Morris International sells cigarettes and reduced-risk products, including heatsticks, vapes, and oral nicotine offerings primarily outside of the US. With the 2023 acquisition of Swedish Match, a leading manufacturer of traditional oral tobacco products and nicotine pouches primarily in the US and Scandinavia, PMI has not only diversified away from smokeable products but also gained a toehold into the US to sell its iQOS heated tobacco product.